Working… Menu

Combination Study of Guadecitabine and Pembrolizumab. (HyPeR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02998567
Recruitment Status : Active, not recruiting
First Posted : December 20, 2016
Last Update Posted : November 17, 2020
Astex Pharmaceuticals, Inc.
Merck Sharp & Dohme Corp.
Institute of Cancer Research, United Kingdom
Information provided by (Responsible Party):
Royal Marsden NHS Foundation Trust

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : June 2021
Estimated Study Completion Date : June 2021